Optimizing Your Weight Loss: Where Can I Give Myself the Wegovy Shot Safely?

Last reviewed: June 17, 2026

Last updated: June 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The Wegovy prescribing information identifies three labeled subcutaneous injection sites — the abdomen, the thigh and the upper arm — and instructs that injection sites be rotated with each dose. That is the labeled answer, and it is worth stating plainly. What no article can supply is the part that actually makes an injection safe: the training the label assigns to your prescriber, delivered for the specific Wegovy presentation you were dispensed. Wegovy now ships in single-dose pens, single-dose syringes and a single-patient-use FlexTouch pen, each with its own Instructions for Use, and the label is explicit that training must match the presentation.

What the Label Says About Sites

The administration section lists the abdomen, thigh or upper arm as the subcutaneous sites and directs that sites be rotated with each dose. It also states that the time of day and the injection site can be changed without the need for a dosage modification.

That last clause answers a question people ask constantly: switching sites does not require a change in dose. The pharmacokinetics support it. The Ozempic labeling for the same active ingredient reports that similar exposure is achieved with subcutaneous administration in the abdomen, thigh or upper arm.

Why Training Is Assigned to the Prescriber

The Wegovy label instructs that, prior to initiation, patients and their caregivers be trained on proper injection technique for the prescribed presentation, and that after training a patient may self-inject if the healthcare provider determines it can be properly administered. It adds a specific carve-out: the FlexTouch pen is not recommended for self-administration by those who are visually impaired.

That is a deliberate allocation of responsibility. The label does not tell the patient how to inject; it tells the prescriber to teach them, and to re-teach them if the presentation changes. An article that substituted itself for that step would be doing something the labeling specifically declines to do.

Presentation Changes the Instructions

The current Wegovy label lists single-dose pens at 0.25, 0.5, 1, 1.7 and 2.4 mg plus a 7.2 mg Wegovy HD pen; single-dose syringes across the same lower strengths; and a single-patient-use FlexTouch pen containing 9.6 mg per 3 mL that delivers four 2.4 mg doses. The FlexTouch presentation has its own warning section on never sharing the device between patients.

Three device families, three sets of Instructions for Use. The label tells prescribers to inform patients which presentation they will receive, ensure training appropriate to it, and instruct them to consult the Instructions for Use for a newly prescribed presentation if it changes. Any generic step list would be wrong for at least two of the three.

What the Label Does Say to Check

One instruction is universal across presentations and worth repeating because it is a quality check rather than a technique: the label directs that the injection be visually inspected prior to each administration and used only if the solution is clear, colorless and contains no particles.

The FDA has separately reported that some compounded GLP-1 products have arrived warm or with inadequate ice packs, and recommends that patients not use any injectable GLP-1 drug that arrives warm or with insufficient refrigeration, since this can affect quality. That is a receiving check, and it applies before anything else does.

Injection Site Reactions in the Trial Data

For context on scale: in placebo-controlled trials of the same molecule, the Ozempic label reports injection site reactions such as discomfort and erythema in 0.2% of treated patients. Local reactions are not the dominant adverse-reaction category for this drug class.

The Wegovy adverse reaction table is led by gastrointestinal events — nausea at 44% versus 16% on placebo, diarrhea 30% versus 16%, vomiting 24% versus 6%, constipation 24% versus 11%. Those are the reactions most likely to prompt a call to a prescriber, not the injection site.

The Practical Path

If you have been prescribed Wegovy and have not received hands-on training for your specific presentation, that is the gap to close, and it is closed by contacting the prescriber or the dispensing pharmacy rather than by reading. The Instructions for Use in your carton is written for the exact device in your hand.

PlexusDx protocols run through a clinical intake and a prescriber, with medications dispensed from licensed 503A compounding pharmacies. Questions about handling a specific dispensed product route to that prescriber and that pharmacy, which is where the answer is both accurate and accountable.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Which injection sites does the Wegovy label list?

The Wegovy prescribing information lists the abdomen, thigh and upper arm as subcutaneous injection sites and instructs that sites be rotated with each dose. It also states that the time of day and the injection site can be changed without the need for a dosage modification. The Ozempic labeling for the same active ingredient reports similar exposure across those three sites.

Does switching injection sites require a dose change?

No. The Wegovy label states directly that the time of day and the injection site can be changed without the need for a dosage modification. Pharmacokinetic data in the Ozempic labeling for semaglutide supports this, reporting similar exposure with subcutaneous administration in the abdomen, thigh or upper arm. Site rotation with each dose is what the label instructs.

Why will not this article give step-by-step injection instructions?

Because the label assigns that job to your prescriber and makes it presentation-specific. Wegovy ships as single-dose pens, single-dose syringes and a single-patient-use FlexTouch pen, each with its own Instructions for Use. The label directs prescribers to train patients on the prescribed presentation and to re-train if it changes, so no single published step list would be correct for everyone.

What should be checked before every injection?

The Wegovy label directs that the injection be visually inspected prior to each administration and used only if the solution is clear, colorless and contains no particles. Separately, the FDA recommends that patients not use any injectable GLP-1 drug that arrives warm or with insufficient refrigeration, since improper storage during shipping can affect the quality of the product.

How common are injection site reactions with semaglutide?

In placebo-controlled trials reported in the Ozempic prescribing information, injection site reactions such as injection-site discomfort and erythema occurred in 0.2% of treated patients. The more frequently reported adverse reactions for this class are gastrointestinal: in the Wegovy adult weight-reduction trials, nausea occurred in 44% versus 16% on placebo and diarrhea in 30% versus 16%.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.